Can we achieve complete remission in locally advanced unresectable Hepatocellular Carcinoma (HCC) by using Sorafenib? Case report and review of literature from Qatar ()
ABSTRACT
Patients with HCC continue to have a dismal prognosis, with 1-year and 3-year survival rates of 36 and 17%, respectively. This is in part related to more than two-thirds of tumors being diagnosed at advanced stages, as well as a substantial portion of patients with early HCC failing to receive potentially curative treatments. Systemic therapy for advanced unresectable HCC limited until the discovery of sorafenib, we are reporting a 53 year patient with unresectable HCC achieved complete remission clinically, radiologically and biochemically with sorafenib which is the first case report.
Share and Cite:
Rasul, K. (2012) Can we achieve complete remission in locally advanced unresectable Hepatocellular Carcinoma (HCC) by using Sorafenib? Case report and review of literature from Qatar.
Modern Chemotherapy,
1, 1-4. doi:
10.4236/mc.2012.11001.
Cited by
No relevant information.